Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole

Breast

Volumn 16, Issue 3, 2007, Pages 252-261

  Skedgel, C ^a   Rayson, D ^a   Dewar, R ^b   Younis, T ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Cancer Care Nova Scotia Halifax   (Canada)

Author keywords

Aromatase inhibitors; Breast cancer; Cost utility analysis; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BELGIUM; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HAZARD RATIO; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 34247847379     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.12.002     Document Type: Article

References (25)

1. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98 9 (2003) 1802-1810
2. ATAC Trialists Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
3. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1091
4. Coombes R.C., Hall E., Snowdon C.F., et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-Updated survival analysis. Breast Cancer Res Treat 88 (2004) 57 (abstr 3)
5. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006 [Epub ahead of print].
6. Thurlimann B., Keshaviah A., Coates A.S., et al., Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
7. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 17 (2005) 1262-1271
8. Carlson R.W., Brown E., Burstein H.J., et al. National comprehensive cancer network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4 1 Suppl. (2006) S1-S26
9. Winer E.P., Hudis C., and Burstein H.J. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 3 (2004) 619-629
10. Monnier A. The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98. Breast 15 Suppl 1 (2006) 21-29
11. Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 2006 [Epub ahead of print].
12. The CEA Registry (2005) Tufts-New England Medical Center, Institute for Clinical Research and Health Policy Studies 〈http://www.hsph.harvard.edu/cearegistry/data/phaseIIpreferenceweights.pdf〉 [Cited 1 June 2005].
13. Algemene Directie Statistiek en Economische Informatie. Mathematische Demographie Sterftetafels 2003 en 2001-2003. Algemene Directie Statistiek en Economische Informatie (2005)
14. Cocquyt V., Moeremans K., Annemans L., et al. Long-term medical costs of postmenopausal breast cancer therapy. Ann Onc 14 (2003) 1057-1063
15. Electronic Medicines Compendium (2005) Pharmacia, Sandwich, Kent UK 〈http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=2484〉 [Cited 23 February 2006]
16. Coombes R.C., Paridaens R., Jassem J., et al., for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 24 18S (2006) LBA527
17. Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics 24 3 (2006) 215-232
18. El Ouagari K, Karnon J, Delea T. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 2006 [Epub ahead of print].
19. Thompson D., Taylor D., and Montoya E. Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 94 S1 (2005) S218 (Abstract 5037)
20. Wilson K., Wordsworth S., Tabberer M., et al. Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model. Eur J Cancer 4 2 Suppl. (2006) 151 (Abstract 354)
21. Lundkvist J., Wilking N., and Holmberg S. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Eur J Cancer 4 2 Suppl. (2006) 152 (Abstract 358)
22. Punglia R., Kuntz K., and Winer E. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 32 (2005) 5178-5187
23. Buzdar A.U., and Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 12 3 Part 2 (2006) 1037s-1048s
24. Lønning P.E. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 17 2 (2006) 217-225
25. Hillner B.E. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101 6 (2004) 1311-1322